Latest Ratios: P/E Ratio 135.8x · EV/EBITDA 12.4x · ROE -1.0%. (2019–2026 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.2B | $1.6B | $500M | $674M | $1.0B | $594M | $2.9B | — | — |
| Enterprise Value | $1.2B | $1.6B | $537M | $730M | $1.1B | $494M | $2.8B | — | — |
| P/E Ratio → | 135.82 | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.19 | 1.62 | 0.59 | 0.88 | 1.48 | 0.85 | 4.53 | — | — |
| P/B Ratio | 4.50 | 5.98 | 1.90 | 2.25 | 3.39 | 1.68 | 8.07 | — | — |
| P/FCF | 15.83 | 31.90 | 18.78 | — | — | — | — | — | — |
| P/OCF | 18.68 | 24.85 | 15.20 | — | — | 21.74 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.61 | 0.63 | 0.96 | 1.56 | 0.71 | 4.34 | — | — |
| EV / EBITDA | 12.38 | 18.27 | — | — | — | 51.90 | 31.76 | — | — |
| EV / EBIT | 18.08 | 24.10 | — | — | — | — | — | — | — |
| EV / FCF | — | 31.69 | 20.17 | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 20.9% | 20.9% | 68.5% | 17.3% | 14.7% | 19.4% | 25.4% | 24.9% | 23.8% |
| Operating Margin | 6.7% | 6.7% | -3.5% | -3.0% | -7.2% | -0.6% | 11.7% | 9.0% | 8.5% |
| Net Profit Margin | -0.3% | -0.3% | -3.6% | -2.8% | -5.9% | -0.9% | -6.9% | 4.6% | 4.2% |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -1.0% | -1.0% | -10.8% | -7.1% | -12.4% | -1.8% | -18.9% | 27.8% | 24.0% |
| ROA | -0.5% | -0.5% | -5.3% | -3.8% | -7.3% | -1.2% | -9.3% | 6.8% | 5.4% |
| ROIC | 17.8% | 17.8% | -6.8% | -4.9% | -12.1% | -1.3% | 25.1% | 17.9% | 13.8% |
| ROCE | 17.8% | 17.8% | -7.1% | -5.5% | -11.4% | -1.0% | 18.9% | 16.6% | 14.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.32 | 0.32 | 0.38 | 0.38 | 0.38 | 0.24 | 0.23 | 2.02 | 2.39 |
| Debt / EBITDA | 0.99 | 0.99 | — | — | — | 8.91 | 0.95 | 3.50 | 4.00 |
| Net Debt / Equity | — | -0.04 | 0.14 | 0.19 | 0.19 | -0.28 | -0.34 | 0.96 | 1.64 |
| Net Debt / EBITDA | -0.13 | -0.13 | — | — | — | -10.47 | -1.39 | 1.66 | 2.74 |
| Debt / FCF | — | -0.22 | 1.39 | — | — | — | — | 3.23 | 11.70 |
| Interest Coverage | 15.57 | 15.57 | -3.50 | -4.42 | -32.37 | -1.87 | -1.08 | 3.44 | 3.85 |
Net cash position: cash ($98M) exceeds total debt ($87M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.05 | 1.05 | 1.07 | 1.25 | 1.25 | 2.29 | 3.19 | 2.18 | 1.43 |
| Quick Ratio | 1.05 | 1.05 | 1.07 | 1.25 | 1.25 | 2.29 | 3.19 | 2.18 | 1.43 |
| Cash Ratio | 0.69 | 0.69 | 0.64 | 0.74 | 0.74 | 1.75 | 2.59 | 1.49 | 0.73 |
| Asset Turnover | — | 1.78 | 1.53 | 1.32 | 1.26 | 1.24 | 1.18 | 1.38 | 1.28 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 16.84 | 16.97 | 24.58 | 27.28 | 22.29 | 21.74 | 30.92 | 43.12 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | 0.3% | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | 339.7% |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.7% | — | — | — | — | — | — | — | — |
| FCF Yield | 6.3% | 3.1% | 5.3% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 1.5% | 0.0% | 0.0% | 0.0% | 2.7% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 1.5% | 0.0% | 0.0% | 0.0% | 3.0% | — | — |
| Shares Outstanding | — | $136M | $135M | $136M | $136M | $136M | $136M | $133M | $133M |
Includes 30+ ratios · 8 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying INNV stock.
InnovAge Holding Corp.'s current P/E ratio is 135.8x. This places it at the 50th percentile of its historical range.
InnovAge Holding Corp.'s current EV/EBITDA is 12.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 34.0x.
InnovAge Holding Corp.'s return on equity (ROE) is -1.0%. The historical average is -0.0%.
Based on historical data, InnovAge Holding Corp. is trading at a P/E of 135.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
InnovAge Holding Corp. has 20.9% gross margin and 6.7% operating margin.
InnovAge Holding Corp.'s Debt/EBITDA ratio is 1.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Clinical labor cost pressure
Metrics are mathematically derived from official filings.
Negative Earnings Make Multiples Unreliable
INNV trades at a trailing P/E of -40.77 and a forward EV/EBITDA of 51.76, which according to the supplied valuation data reflects depressed earnings rather than a meaningful earnings multiple, so pricing must be anchored to sales and book value instead.
With trailing earnings still negative, the P/E ratio carries no interpretive weight and should be excluded from relative comparisons. The forward EV/EBITDA of 51.76 implies the market is capitalizing a recovery in EBITDA that has not yet appeared in reported results, which suggests investors are pricing in a successful margin turnaround. The P/S of 1.43 and P/B of 4.62 are more informative here, and the P/B premium relative to a business with an accumulated deficit suggests the market is assigning value to the participant base and recurring capitated revenue rather than to tangible asset backing.
Margin Recovery Still Unproven Across Cycles
Gross margin has risen from 16.8% to 21.9% over the last ten quarters while operating margin swung from -6.0% to 7.6%, and based on the reported figures this improvement rests on only a few recent quarters.
The expansion in gross margin indicates a better spread between capitated revenue and medical cost, but the operating margin remains thin relative to the gross margin, implying that center-level and corporate overhead still absorb most of the gross profit gain. The net margin of 7.4% in the latest quarter is flattered relative to the 3.2% reported in the prior quarter, which suggests that single-period results may overstate sustainable earning power. Investors should monitor whether operating margin holds above 6% through a full fiscal cycle before treating the recovery as structural.
Returns Turning Positive From a Deficit Base
ROIC has moved from -2.7% in mid-2025 to 5.9% in the latest quarter and ROE from -4.6% to 7.0%, which according to reported figures indicates a shift from value destruction toward thin positive returns.
The reversal in ROIC and ROE appears driven primarily by improved operating margins rather than by any material gain in capital efficiency, since asset turnover has held near 0.37 to 0.47 throughout the period. Returns remain low in absolute terms and may not yet cover the company's cost of capital given its capital-intensive, site-based footprint. The trend is encouraging, but a sustained ROIC above 8 to 10 percent would be needed before the business could credibly be described as compounding returns.
Low Debt Ratios Mask Interest Coverage Volatility
Debt-to-equity has stayed between 0.29 and 0.41 across ten quarters, but interest coverage swung from -16.71 to 163.90, which according to the reported ratios reflects a denominator effect from small interest expense rather than a clear improvement in debt service capacity.
A debt-to-equity ratio below 0.41 indicates modest leverage relative to equity, and the company's balance sheet does not appear to face near-term refinancing pressure based on the supplied figures. However, interest coverage ratios of 163.90 and 18.57 in recent quarters are not comparable to the negative values earlier, because the underlying interest expense base is small and volatile. Investors should treat coverage as a weak signal and focus instead on operating cash flow against fixed center costs.
Current Ratio Near One Leaves Thin Buffer
The current ratio has ranged from 0.78 to 1.26 over ten quarters and stood at 1.16 in the latest quarter, which according to reported balance sheet figures provides only a narrow cushion against short-term obligations.
Because inventory is negligible for a services provider, the quick ratio equals the current ratio and offers no additional discrimination, so the relevant question is whether receivables and cash can cover near-term payables and accrued medical claims. A current ratio dipping below 1.0, as occurred in Q3 2025 and Q3 2026, would indicate that current liabilities exceeded current assets, which under stress could compress the company's ability to absorb IBNR true-ups or delayed capitated receivables. This thin buffer warrants close monitoring rather than an assumption of comfort.
Peer Multiples Obscure Capital Intensity Gap
Relative to ALHC and OSCR, INNV's ROE of 7.0% and net margin of 7.4% look competitive, but based on reported figures its P/B of 4.62 and EV/EBITDA of 51.76 suggest the market is paying for a turnaround that has not yet reached the peer group's return profile.
The most commonly misapplied lens for this business is price-to-book, because INNV's book value includes substantial goodwill of $142.0M and net PP&E of $184.0M, making a P/B premium appear rich even though the physical PACE center footprint is an operating necessity rather than surplus capital. Analysts should instead adjust for center-level contribution margin and participant-months per center, which isolate the operating economics of the site-based model from corporate overhead. Investors should monitor whether the valuation premium narrows as center utilization improves and returns move sustainably above cost of capital.